EXPERIENCE OF TOFACITINIB USING IN THERAPY OF ULCERATIVE COLITIS IN REAL CLINICAL PRACTICE

AIM: to demonstrate the first Russian experience with the use of tofaciminib (TOFA) for the treatment of moderate and severe UC in real clinical practice.

PATIENTS AND METHODS: eighty-five patients with UC (aged 41.38±14.69 years, average disease duration 9.55±5.27 years, mild UC – 3.5%, moderate UC – 41.2%, severe – 52.9%, acute severe UC – 2.6%), resistant to corticosteroid therapy (36.5%) and biological agents (61.2%), were prescribed with TOFA at an induction dose of 10 mg 2 times a day, followed by a decrease in the dose to a maintenance dose (5 mg 2 times a day). Early clinical response, clinical and endoscopic remission, prevalence and dynamic of extraintestinal manifestations were assessed at 8 and 12 weeks of treatment, as well as safety and tolerability.

RESULTS: Sixty-eight (80.0%) patients completed induction treatment with TOFA for 8 weeks, other patients continue to receive TOFA. A quick response within one week was detected in 41 (50.6%) patients, on average, on the 5th day of therapy. At the end of induction, 52 (76.5%) patients achieved clinical remission, 3 (4.4%) achieved a clinical response, 13 (19.1%) patients showed no positive changes. Of the 53 patients observed over 12 weeks, 41 (77.4%) had clinical remission, 6 (11.3%) had clinical improvement, and 6 (11.3%) patients had no response to the treatment. The changes of extraintestinal manifestations were positive: 55.2% of patients at week 8 and 77.8% of patients at week 12 showed clinical improvement, mainly in relation to the joint syndrome. One episode of herpes zoster infection, one case of anemia, were identified dur-ing 12 weeks of follow-up.

CONCLUSION: TOFA in UC is effective in achieving a rapid clinical response, clinical remission and mucosal healing in patients who do not adequately respond to therapy with basic as well as biological drugs. Tofacitinib is an effective and safe therapeutic option for this challenging patient population.

1. Khalif I.L., Shapina M.V., Golovenko A.O. et al. Chronic inflam-matory bowel diseases: the course and treatment methods in Russian Federation (Results of multicenter population-based one-stage observational study). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018; no. 28(3), pp. 54-62. https://doi.org/10.22416/1382-4376-2018-28-3-54-62. (In Russ.).

2. Ford AC, Sandborn WJ, Khan KJ et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106:644-659 (quiz 660).

3. Shapina M.V., Khalif I.L., Golovenko A.O. et al. Features of the course of ulcerative colitis during therapy with infliximab. Farmateka. 2015; no. 15, pp. 40-43. (In Russ.).

4. Amiot A, Serrero M, Peyrin-Biroulet L, et al. One-year effective-ness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46:310-321.

5. Belousova E.A., Khalif I.L., Abdulganieva D.I. et al. Socio-demographic characteristics, features of the course and treatment patterns for inflammatory bowel diseases in Russia. The results of two multicenter studies. Almanach of Clinical Medicine. 2018; no. 46 (6), pp. 445-463. doi: 10.18786/2072-0505-2018-46-6–445-463. (In Russ.).

6. Banerjee S, Biehl A, Gadina M et al. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs. 2017;77(5):521-546. doi: 10.1007/s40265-017-0701-9.

7. Neurath M. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:269-78.

8. Shapina M.V., Khalif I.L. Efficacy and safety of tofacitinib in ulcerative colitis (review). Koloproktologia. 2018; no. 3, pp. 94-102. DOI: 10.33878/2073-7556-2018-0-3-94-102. (In Russ.)

9. Nasonov E.L., Abdulganieva D.I., Fairushina I.F. The use of Tofacitinib in the treatment of inflammatory bowel disease. Therapeutic Archive. 2019; 91 (2): 26–. DOI: 10.26442/00403660.2019.02.000155. (In Russ.).

10. Sandborn WJ, Su C, Sands BE et al. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723-1736.

11. Panes J, Su C, Bushmakin AG, Capperelli JC, et al. Randomized trial of tofacitinib in active ulcerative colitis: analysis of effi-cacy based on patient-reported outcomes. BMC Gastroenterol. 2015; 15(1): 15:14.

12. Panes J, Vermeire S, Lindsay JO et al. Tofacitinib in patients with ulcerative colitis: health-related quality of life in Phase 3 ran-domized controlled induction and maintenance studies. J Crohns Colitis. 2017; 12(2):145-156.

13. Sandborn WJ, Panés J, D'Haens GR et al. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol. 2019;17(8):1541-1550. doi: 10.1016/j.cgh.2018.11.035.

14. Weisshof R, Aharoni Golan M, Sossenheimer PH et al. Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019;64(7):1945-1951. doi:10.1007/s10620-019-05492-y. Epub 2019 Feb 7.

15. Ungaro R, Fenster M, Dimopoulos C et al. Real-world effec-tiveness of tofacitinib in ulcerative colitis: a multi-centre study. Journal of Crohn's and Colitis. 2019;13:S274–S275, https://doi.org/10.1093/ecco-jcc/jjy222.468.

16. Lair-Mehiri L,Stefanescu S, Vaysse T et al. Real-world tofaci-tinib effectiveness and safety in patients with refractory ulcer-ative colitis. Journal of Crohn's and Colitis. 2019; 13:S478–S479, https://doi.org/10.1093/ecco-jcc/jjy222.839.

17. Hanauer S, Panaccione R, Danese S et al. Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2. Journal of Crohn's and Colitis. 2018;12:S046–S048, https://doi.org/10.1093/ecco-jcc/jjx180.061.

18. Feagan BG, Dubinsky MC, Lukas et al. Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib 8-week induction non-responders. Journal of Crohn's and Colitis. 2018; 12:S050, https://doi.org/10.1093/ecco-jcc/jjx180.064.

19. Rubin DT, Ashaye AO, Zhang Y et al. Comparative efficacy and safety of tofacitinib and biologics as induction therapy for mod-erately-to-severely active ulcerative colitis: a systematic review and network meta-analysis. Presented at: 25th United European Gastroenterology Week 2017. Barcelona, Spain, 28 October, 2017(1).

20. Bonovas S, Lytras T, Nikolopoulos G et al. Systematic review with network meta-analysis: comparative assessment of tofaci-tinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(4):454-465. doi:10.1111/apt.14449. Epub 2017 Dec 4.

21. Singh S, Fumery M, Sandborn W et al. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(2):162-175. doi: 10.1111/apt.14422. Epub 2017 Dec 4.